glp-1 prescriptions growth slowing 2024 The Multi-Sector Impacts of GLP-1RA Drugs GLP-1 Receptor Agonist Market Size
Description
Additionally, 25 patients (16%) reported double dosing within 24 h of the first dose and 12 (8%) patients reported injecting a once weekly formulation daily
As it evolves its product line, Novo Nordisk is facing lawsuits at the state and federal levels, alleging that its GLP-1 drugs, like Wegovy, have caused serious injuries to some patients
This could increase the risk of hypoglycemia, particularly in individuals who are also taking other glucose-lowering medications
The clinical trial data proves this conclusively
